ライフサイエンスコーパス: haemolysis

1 ds (DPPH, ORAC and erythrocyte resistance to haemolysis).

2 rds hydrogen peroxide and on surface-induced haemolysis.

3 altering red blood cell rheology and causing haemolysis.

4 nd no evidence of hepatitis, cholestasis, or haemolysis.

5 c sucrose solutions at pH 6) supported their haemolysis.

6 Cytochalasin B prevented haemolysis.

7 of individuals at risk of primaquine-induced haemolysis.

8 o sustained reticulocytopenia, to near-fatal haemolysis.

9 ver, abnormal liver function tests, and mild haemolysis.

10 ompromised, the RBCs are more susceptible to haemolysis.

11 l mutant also restores full contact-mediated haemolysis activity to this bacterium.

12 lation of eight mutants that failed to cause haemolysis, all of which had transposon insertions in ge

13 nillin or 5-hydroxymethyl, and urea) reduced haemolysis, an effect not due to increased oxygen affini

14 Hydroxyurea treatment reduces haemolysis and anaemia by increasing foetal haemoglobin,

15 ubarachnoid haemorrhage is often followed by haemolysis and concomitant oxidative stress, and is freq

16 nto the mechanism of streptolysin S-mediated haemolysis and have implications for the development of

17 ucture is a key step for membrane insertion, haemolysis and insecticidal activity.

18 SAT6 has recently been demonstrated to cause haemolysis and macrophage lysis.

19 There has been no significant haemolysis and no device-related complications.

20 12 patients reported serious adverse events; haemolysis and pyrexia were the most common (each occurr

21 oposed direct link between contact-dependent haemolysis and Shigella entry, and demonstrate that IpaB

22 hildren showed evidence of treatment-related haemolysis, and the mean maximum decrease in haemoglobin

23 although the importance of chronic anaemia, haemolysis, and vasculopathy has been established.

24 utropenic typhlitis, pancreatitis, and acute haemolysis are very rare.

25 A simple test represented by this haemolysis assay would be useful especially in less affl

26 may result in a ten-fold increase in sample haemolysis, compared to the recommended guideline proced

27 rated, samples were processed to obtain full haemolysis curves at precise times.

28 progressive changes in the profile of their haemolysis curves, as the curves migrated towards lower

29 showed no change in profile of the migrating haemolysis curves, suggesting that their PCl distributio

30 on (2 [6%]), and one (3%) each with anaemia, haemolysis, fatigue, and a neurological, metabolic, resp

31 ched the threshold of clinically significant haemolysis (fractional haematocrit reduction >25%) in G6

32 Haemolysis has features which suggest that it is linked

33 or dehydrating cells to attain resistance to haemolysis in a selected hypotonic medium.

34 re was no evidence of clinically significant haemolysis in any patient.

35 tioxidant power) and inhibition of oxidative haemolysis in erythrocytes.

36 nt of Plasmodium vivax malaria and can cause haemolysis in G6PD deficient subjects.

37 he potential to cause clinically significant haemolysis in G6PD heterozygous females who are reported

38 primaquine or tafenoquine) is complicated by haemolysis in individuals with glucose-6-phosphate dehyd

39 However, primaquine can trigger haemolysis in patients with a deficiency in glucose-6-ph

40 However, concerns about dose-dependent haemolysis in people with glucose-6-phosphate dehydrogen

41 ial was designed to measure efficacy and not haemolysis in relation to G6PD genotype and that the het

42 Controversies include the role of haemolysis in sickle cell disease pathophysiology, optim

43 At pH 6, haemolysis occurred even in oxygenated samples.

44 as significantly inhibited with little or no haemolysis occurring at 4 degrees C.

45 ls and loss of Dot/Icm T4SS-mediated contact haemolysis of erythrocytes.

46 Eculizumab inhibits the intravascular haemolysis of PNH, reduces transfusion requirements, sta

47 iglyceridaemia, but there was no evidence of haemolysis or microangiopathy.

48 RSA) and fungi, without inducing significant haemolysis over a wide range of concentrations.

49 that at temperatures < or = 15 degrees C the haemolysis rate was significantly inhibited with little

50 These findings are consistent with haemolysis requiring HbS polymerisation and support the

51 r varieties, as assessed by the ORAC and the haemolysis resistance assays.

52 Many acute and chronic anaemias, including haemolysis, sepsis and genetic bone marrow failure disea

53 tion, microneutralisation, and single radial haemolysis (SRH).

54 The intravascular haemolysis that is the clinical hallmark of PNH is a con

55 r [11%] of 37), chest pain (two [5%] of 37), haemolysis (two [5%] of 37), and neutropenia (two [5%] o

56 designed to characterise primaquine-induced haemolysis using a holistic Bayesian analysis of all pub

57 When alpha toxin-dependent haemolysis was measured on erythrocytes at various tempe

58 Haemolysis was reduced in patients on long-term (>5 mont

59 Haemolysis was substantially greater and a larger propor

60 Haemolysis was temperature- and pH-dependent.

61 Patterns of haemolysis were compared between G6PD wild-type and G6PD

62 e rate of sample laboratory rejection due to haemolysis when commonly practiced deviations from the g

63 s has been the appearance of complete (beta) haemolysis when grown in the presence of blood.

64 adherence to the vascular endothelium and by haemolysis, which results in endothelial cell activation

65 rent work addresses the hypothesis that this haemolysis will provide a novel diagnostic and prognosti